4142:TPE
Adimmune Corp
17,80 NT$
arrow_downward
−0,56%(−0,10) 1 p
22. okt, 13:30:07 GMT +8 · TWD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4142 põhistatistika genereerimine…
Ava
17,90 NT$
Kõrge
17,95 NT$
Madal
17,75 NT$
Turu kapit.
7,65 mld
Keskm. maht
1,06 mln
Maht
328,73 tuh
52 näd kõrgeim
22,50 NT$
52 näd madalaim
16,40 NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29 mln
Töötajate arv
564
Ava
17,90 NT$
Kõrge
17,95 NT$
Madal
17,75 NT$
Turu kapit.
7,65 mld
Keskm. maht
1,06 mln
Maht
328,73 tuh
52 näd kõrgeim
22,50 NT$
52 näd madalaim
16,40 NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29 mln
Töötajate arv
564
Uudised
Veebiallikatest ja uudistepartneritelt
KED Global
·
8 minuti eest
SK Hynix abandons Solidigm Nasdaq IPO after shareholder backlash
24/7 Wall St.
·
9 minuti eest
Super Micro Has Lost 60.86% Since It Was Tapped for the S&P 500. Index Funds Like VOO Had to Buy It Anyway
GuruFocus
·
8 minuti eest
Dow Inc (DOW) Shares Surge 4.7% -- What GF Score of 73 Tells Inv
Reuters
·
28 minuti eest
S&P 500, Nasdaq end lower as revived AI doubts spark tech selloff
Profiil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Teave üksuse Adimmune Corp kohta